Global Comprehensive Genomic Profiling Cancer Biomarkers Market Research Report – Segmented By Technology (Next-Generation Sequencing (NGS), Sanger Sequencing, Microarrays); By Cancer Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Other Cancers (e.g., prostate, pancreatic)); By Biomarker Type (Genomic Biomarkers (Mutations, Copy Number Alterations), Protein Biomarkers); By Application (Targeted Therapy Selection, Clinical Trial Selection, Prognosis and Risk Stratification, Minimal Residual Disease Detection, Companion Diagnostics ); By End User (Hospitals & Clinics, Research Institutions, Pharmaceutical & Biotechnology Companies) and Region - Size, Share, Growth Analysis | Forecast (2024 – 2030)

The Global Comprehensive Genomic Profiling Cancer Biomarkers Market size is valued at USD 9.7 billion in 2023.

 The worldwide Global Comprehensive Genomic Profiling Cancer Biomarkers Market growth is estimated to be 10.6% from 2024 to 2030.

 The Global Comprehensive Genomic Profiling Cancer Biomarkers Market is segmented By Technology (Next-Generation Sequencing (NGS), Sanger Sequencing, Microarrays); By Cancer Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Other Cancers (e.g., prostate, pancreatic)); By Biomarker Type (Genomic Biomarkers (Mutations, Copy Number Alterations), Protein Biomarkers); By Application (Targeted Therapy Selection, Clinical Trial Selection, Prognosis, and Risk Stratification, Minimal Residual Disease Detection, Companion Diagnostics ); By End User (Hospitals & Clinics, Research Institutions, Pharmaceutical & Biotechnology Companies) and By Region.

With opportunities for growth in liquid biopsies, AI integration, multi-omics profiling, companion diagnostics, and early cancer diagnosis, the market for CGP cancer biomarkers appears to have a bright future.

The market for CGP cancer biomarkers was affected by the COVID-19 pandemic in a variety of ways. Early setbacks were from changes in resources and postponements of clinical trials. On the other hand, the pandemic also brought attention to the significance of personalized treatment, which may eventually help CGP.